LONDON--(EON: Enhanced Online News)--Technavio’s latest report on the global cervical cancer diagnostic testing market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
“Liquid-based or thin-layer preparations, computer-assisted screening methods, and new generation HPV testing methods are several new techniques used to enhance the quality and adequacy of the Pap smear test and its interpretation. These new tests will decrease the number of unsatisfactory and ambiguous results, and provide reliable results consistently.”
By technology, this market is segmented into enzyme-linked immunosorbent assay (ELISA), fluorescence in-situ hybridization (FISH), nucleic acid sequence based amplification (NASBA), polymerase chain reaction (PCR), and multichromatic staining and microscopy. ELISA and PCR are the most widely adopted techniques in the market.
The global cervical cancer diagnostic testing market is expected to post a CAGR of almost 7% in the forecast period. This market is mainly driven by the increasing awareness on women’s health and wellness. Pap smear is the most commonly uses testing method, accounting for 81.34% of the market in 2015. The human papillomavirus (HPV) testing is quickly gaining popularity, and is expected to showcase a steep growth curve in the forecast period.
Request a sample report: http://www.technavio.com/request-a-sample?report=55048
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top four emerging trends driving the cervical cancer diagnostic testing market according to Technavio healthcare and life sciences research analysts are:
- Development of new diagnostic platforms
- Expansion into emerging markets
- Emergence of novel biomarkers
- Rise in use of HPV home-testing kits
Development of new diagnostic platforms
Co-testing with HPV and pap smear is the latest trend in the market. Various agencies in the US have set guidelines for cervical cancer testing, which is being widely adopted in other countries as well. These guidelines mandate that women aged over 30 should undergo cervical cancer diagnostic tests once every five years.
Talking about the emergence of new testing methodologies due to significant investments, Bharath Palada, one of the lead market research analysts at Technavio for in-vitro diagnostics research says, “Liquid-based or thin-layer preparations, computer-assisted screening methods, and new generation HPV testing methods are several new techniques used to enhance the quality and adequacy of the Pap smear test and its interpretation. These new tests will decrease the number of unsatisfactory and ambiguous results, and provide reliable results consistently.”
Expansion into emerging markets
To maximize revenue generated, global vendors are venturing into niche markets in developing countries. For instance, QIAGEN entered a partnership with Chittaranjan Cancer Institute in India to serve quality healthcare to women in low-resource areas. In addition, they also collaborated with Merck, managing to provide nearly five million free vaccines and expanding the already existing HPV test donation program.
Prominent vendors like Cancer Genetics are involved in acquisition and expansion. The company acquired BioServe for its biomarker analysis, next generation sequencing, and oncology diagnostics laboratory facilities. Moves like this helps the companies to enhance their pipeline for the non-invasive cervical cancer testing facilities in developing countries, where cervical cancer is the leading cause of cancer death in women.
Emergence of novel biomarkers
Many leading vendors and world-acclaimed universities are investing in R&D to detect and confirm surrogate biomarkers for HPV infections. These biomarkers will allow for accurate monitoring of molecular expressions in histological or cytological specimens. Quest Diagnostics acquired a no-exclusive patent license from the National Institute of Health (NIH) to develop the telomerase RNA component (TERC) test for screening of cervical cancer, which is forecast to show more accurate and efficient results than either Pap or HPV testing. The continuous research is projected to invent new biomarkers that will make way for improved cervical cancer detection.
Rise in use of HPV home-testing kits
“Vendors in the market have developed innovative home-based products, which can provide quick and accurate test results. The British Medical Journal has reported that the availability and use of self-test kits had aided in diagnosing almost double the number of women affected. These tests are designed to be performed by healthcare professionals with minimal healthcare training or even by individuals,” says Bharath.
For instance, Ohio State University Comprehensive Cancer Center is currently involved in development of a self-test for HPV testing cervical cancer in Ohio Appalachia. Additionally, emerging companies like GynaeHealth are focusing on launching HPV assay kits for cervical cancer screening at home. The presence of such products in the market will provide access to a greater number of women to perform HPV tests at home. This will eventually lead to an increase the number of women undergoing cervical cancer screening.
Browse Related Reports:
- Global Cancer Diagnostics Devices Market 2016-2020
- Global Prostate Cancer Drugs Market 2016-2020
- Global Nucleic Acid Testing Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like oncology, women’s health, and life science research tools. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.